Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
sage-10k_20191231.htm
Sage Therapeutics, Shionogi ink deal for MDD treatment
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
An Update On Sage Therapeutics (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics surges 70% after depression drug breakthrough
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
